SERIF BIOMEDICINES
LIVE

Serial Number

99617886

Owner

Serif Biomedicines, Inc.

Attorney

Christina M. Licursi

First Use Date

Sep 1, 2024

Filing Date

Jan 27, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SERIF BIOMEDICINES Trademark

Serial Number: 99617886

SERIF BIOMEDICINES is a trademark filed by Serif Biomedicines, Inc. on January 27, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Serif Biomedicines, Inc.

55 Cambridge Parkway, Suite 800E
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

January 27, 2026

Registration Date

Not Registered

First Use Anywhere

September 1, 2024

First Use in Commerce

September 1, 2024

Goods & Services

Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services

Biological and chemical agents for scientific and research use, namely, nucleic acids for use in the manufacture of pharmaceuticals, reagents for pharmaceutical research purposes, and cells for scientific and research use

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculoskeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculoskeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculoskeletal and genitourinary systems, and viruses and infectious diseases

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 26, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 26, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 1, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 1, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 1, 2026 CNRT
ASSIGNED TO EXAMINER
May 26, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 19, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 27, 2026 MAFR
NEW APPLICATION ENTERED
Jan 27, 2026 NWAP